This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Intervention Study to Investigate Supplemental Oxygen in COPD

This study is currently recruiting participants.
See Contacts and Locations
Verified May 2017 by Margareta Emtner, Uppsala University
Sponsor:
Collaborators:
Umeå University
Karolinska Institutet
University of California, Los Angeles
Information provided by (Responsible Party):
Margareta Emtner, Uppsala University
ClinicalTrials.gov Identifier:
NCT01783808
First received: January 16, 2013
Last updated: May 9, 2017
Last verified: May 2017
  Purpose

The purpose of this trial is to study the effects on exercise capacity, physical activity, inflammatory markers and quality of life of supplemental ambulatory oxygen, to be used during physical activity, in patients with COPD who are normoxic at rest but hypoxemic during a six-min walk test.

Our hypothesis is that if patients are able to use supplemental oxygen they will be more physically active and thereby improve health related quality of life.


Condition Intervention
COPD Physical Activity Sedentary Other: Supplemental oxygen

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Outcomes Assessor
Primary Purpose: Treatment
Official Title: Effects on Exercise Capacity, Physical Activity and Quality of Life Using Ambulatory Oxygen in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Desaturate Only During Exercise

Resource links provided by NLM:


Further study details as provided by Margareta Emtner, Uppsala University:

Primary Outcome Measures:
  • Six-minute walk test [ Time Frame: Change from baseline to 6 months ]
    The patient is supposed to walk as long as possible during six minutes.


Secondary Outcome Measures:
  • Physical activity level [ Time Frame: Change from baseline to 6 months ]
    Physical activity will be measured with an activity monitor (accelerometer) and by a questionnaire


Other Outcome Measures:
  • Health related quality of life [ Time Frame: Change from baseline to six months ]
    EuroQol five-dimension questionnaire, St Georges Respiratory Questionnaire, Hospital Anxiety and Depression Scale, COPD Assessment Test, Medical Research Council scale

  • Inflammatory markers [ Time Frame: Change from baseline to 6 months ]
    C-reactive protein, Leucocytes, Thrombocytes, Erythrocytes, Hemoglobin


Estimated Enrollment: 144
Actual Study Start Date: November 2012
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Supplemental oxygen

Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.

In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used.

Other: Supplemental oxygen

Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.

In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used.

No Intervention: Control group
The control group will not get supplemental oxygen during physical activity but they will get the same physical activity intervention as the intervention group.

Detailed Description:

Study design The study will employ a parallel design for 6 months including 144 patients (72 patients/group). Patients will be randomized to intervention or control group. The intervention comprises supplemental oxygen to be used during physical activity for 6 months. The control group will receive the same physical activity instructions as the intervention group during the 6 months, but they will not be able to use supplemental oxygen during physical activity.

The study will be a prospective, randomized, single-blind multi-centre intervention study with an intention to treat design (last value carry over). Inclusion will continue until 144 patients have fulfilled the 6 months. Patients will be tested at baseline and after 6 months. There will also be a follow-up after 12 months comprising questionnaires. The study will include centers in Sweden Norway, Finland, and Estonia.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • COPD, Arterial Oxygen Saturation > 8 kilopascal at rest
  • Oxygen Saturation ≤ 88% and a fall in Oxygen Saturation ≥ 4% during a six-minute walk test in ambient air
  • No exacerbation within 4 weeks prior to the study
  • Post-bronchodilator forced expiratory volume at one second < 80% predicted and forced expiratory volume at one second /Vital capacity < 0.7
  • Oxygen Saturation ≥ 92 % during a walk test in self-selected pace with supplemental oxygen. Patients should use supplemental oxygen 10 minutes before the test starts.
  • Non-smoker (smoke free for ≥ 6 months)
  • Interest in being physically active

Exclusion Criteria:

  • Arterial carbon dioxide > 6.5 kilopascal at rest
  • Orthopedic, neurologic or mental impairments that would limit physical activity
  • Neoplastic disease that is anticipated to influence survival
  • Patients exercising with supplemental oxygen
  • Long-term oxygen therapy
  • Patients with arterial auricular fibrillation and/or heart disease that might hinder physical activity as judged by the physician
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01783808

Contacts
Contact: Margareta I Emtner, PhD +46184714761 margareta.emtner@neuro.uu.se
Contact: Karin Wadell, PhD +4690786 9887 karin.wadell@physiother.umu.se

Locations
Sweden
Akademiska sjukhuset Recruiting
Uppsala, Sweden, 751 85
Contact: Margareta I Emtner, PhD    +46184714761    margareta.emtner@neuro.uu.se   
Contact: Christer Janson, Professor    +46186114115    christer.janson@medsci.uu.se   
Principal Investigator: Margareta I Emtner, PhD         
Sponsors and Collaborators
Uppsala University
Umeå University
Karolinska Institutet
University of California, Los Angeles
Investigators
Study Chair: Christer Janson, Professor Department of Medical Sciences, Uppsala University
  More Information

Responsible Party: Margareta Emtner, PhD, Associate Professor, Uppsala University
ClinicalTrials.gov Identifier: NCT01783808     History of Changes
Other Study ID Numbers: Ambox-2012-MEUP
Uppsala University ( Other Grant/Funding Number: Uppsala Ethical Review board )
Study First Received: January 16, 2013
Last Updated: May 9, 2017

Keywords provided by Margareta Emtner, Uppsala University:
COPD
Physical capacity
Physical activity
Inflammatory markers
Health related quality of life

Additional relevant MeSH terms:
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on June 23, 2017